Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies

Objectives: Clinical benefits of immune-checkpoint blockade (ICB) versus standard chemotherapy have been established in unselected non-small cell lung cancer (NSCLC). However, the response to ICB therapy among patients is heterogeneous in clinical practice. Materials and Methods: We retrospectively...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncoimmunology
Главные авторы: Ma, Si-Cong, Tang, Xin-Ran, Long, Li-Li, Bai, Xue, Zhou, Jian-Guo, Duan, Zhi-Jiao, Wang, Jian, Fu, Qiang John, Zhu, Hong-Bo, Guo, Xue-Jun, Zhang, Yan-Pei, Guo, Ze-Qin, Wu, De-Hua, Dong, Zhong-Yi
Формат: Artigo
Язык:Inglês
Опубликовано: Taylor & Francis 2021
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078693/
https://ncbi.nlm.nih.gov/pubmed/33996262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1909296
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы